<DOC>
	<DOCNO>NCT01235013</DOCNO>
	<brief_summary>Maraviroc antiretroviral drug belongs family CCR5 coreceptor inhibitor . It proven effective increase CD4 lymphocyte count treat na√Øve patient , irrespective viral load . The investigator hypothesize add Maraviroc antiretroviral treatment discordant patient , define CD4 lymphocyte count 200 cell /mm3 last year , could lead immunological recovery . 60 patient include unicentric , prospective , randomize stratify clinical trial . They randomize either continue usual high activity antiretroviral therapy ( HAART ) treatment receive 300 mg Maraviroc every 12 hour plus usual treatment . After 24 week , lymphocyte count assess , well safety , clinical progression , immunological profile patient potential benefit Maraviroc HIV+ cirrhotic patient .</brief_summary>
	<brief_title>Effect Maraviroc ( MCV ) Immunological Recovery HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3</brief_title>
	<detailed_description />
	<mesh_term>Maraviroc</mesh_term>
	<criteria>18 year age old HIV infection Patients receive HAART treatment least one year sustain viral load equal 200 copies/ml Viral load equal 200 copies/ml screen visit Discordant patient : patient without increment 50 copy /ml CD4 lymphocyte last year Patients expect adherence HIV treatment 90 % accord physician . Signed informed consent form Pregnancy breast feed woman plan pregnancy study duration Any contraindication treatment Maraviroc X4 tropism inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>HIV-1 infection</keyword>
	<keyword>Maraviroc</keyword>
	<keyword>CD4 lymphocyte count</keyword>
</DOC>